FDA Clearance Tracker · P250024
Trilogy Transcatheter Heart Valve System
Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Mar 17, 2026
Approved
Time to decision
260 days
Received Jun 30, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P250024
- Device name
- Trilogy Transcatheter Heart Valve System
- Applicant
- JenaValve Technology, Inc.
- Applicant location
- Irvine, CA
- Received
- Jun 30, 2025
- Decided
- Mar 17, 2026
- Decision
- Approved
- Supplements
- 5 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
The Trilogy Transcatheter Heart Valve System is indicated for the treatment of symptomatic, severe native tricuspid aortic valve regurgitation (not due to acute endocarditis, rheumatic heart disease, or acute aortic dissection) in patients who are judged by a Heart Team, including a cardiac surgeon, to be at high or greater risk for surgical aortic valve replacement (i.e., predicted risk of surgical mortality >=8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NPT. The earliest in FDA's data is P100041, decided Nov 2, 2011.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
Other decisions for JenaValve Technology, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.